Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm maribavir study in pediatric and adolescent transplant recipients with CMV infection
CTR20240855Phase 3Suspended
- Sponsor
- Takeda
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of maribavir in cytomegalovirus disease (CMV), sponsored by Takeda. Primary endpoints: Pharmacokinetic parameters and Serious adverse events and adverse events. Started Jul 2024; status: suspended.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on CTR20240855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240855.